Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Arthur Franken, Partner, Gilde Healthcare Partners Arthur joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals, FlowCardia (acquired by C. R. Bard), Moximed and MTM Laboratories (acquired by Roche). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure, BG Medicine (IPO on NASDAQ) and Pieris. He represents Gilde on the board of Moximed and Symphogen. He served as a board member for FlowCardia (until its trade sale to C. R. Bard), MTM Laboratories (until its trade sale to Roche) and observed on the boards of Agendia and AMT (until its IPO on Euronext). Prior to joining Gilde he gained experience in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national. Bassam Damaj, CEO & President, Apricus Biosciences Bassam has been the President, Chief Executive Officer and a director since December 2009. Dr. Damaj served as Chairman of the Board of Directors from October 2010 to April 2012. He has served as a member of our ad hoc Finance Committee since 2010. He is the co-founder of Celltek Biotechnology and served as a director from 1997 until 2000. He is also the founder of R&D Healthcare. He is a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a director of Bio-Quant since its inception in June 2000. He has also served as the Group Leader for the Office of New Target Intelligence and a Group Leader for immunological and inflammatory disease programs at Tanabe Research Laboratories, U.S.A., Inc., as a senior scientist and member of the senior staff board of the drug discovery department at Pharmacopeia Inc., and as a visiting scientist at Genentech Inc., Pfizer Inc. and the National Institutes of Health (NIH). He also served as an independent director for CreAgri, Inc. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University. Dr Benedkt Timmerman, CEO, Genticel Benedikt founded Genticel (initially called BT Pharma) in 2001 and is currently CEO of the company. Prior to Genticel, Benedikt had a successful career at NOVARTIS (1996 – 2000) and its predecessor company SANDOZ (1991 - 1996). In these companies, he held various management positions, including Head of Biotechnology, Sandoz Seeds Eu, Senior Director Research & Development of Novartis Seeds – Eu, member of the European Executive Committee and member of the corporate Novartis Technology Licensing and Acquisition team. Dr Timmerman is also board member of several organisations, including BioMedicalAlliance, a French Biotech Association and Biotech Representative of the Industrials Club of the ‘Cancer Pole GSO’ in France. Benedikt is of Belgian nationality, holds a PhD in Molecular Genetics from the University of Ghent, Belgium (1986) and an MBA from INSEAD, Fontainebleau, France (1990-1991). Bill Blair, BioQuarter Bill joined BioQuarter as the Head of Business Creation in April 2011. He is responsible for managing the launch of new companies from the BioQuarter portfolio, as well as leading a team of professionals in the development of further new businesses based on world-leading medical research from the University of Edinburgh’s College of Medicine and Veterinary Medicine and NHS Lothian. Prior to joining Edinburgh BioQuarter, Mr Blair was Investment Director at Scottish Widows Investment Partnership (SWIP) for eight years where he established and led its venture capital investment programme before setting up his own venture capital strategic consultancy business, HVS Advisers. Mr Blair also previously headed up pharmaceutical company research for stockbrokers Nomura International, Fleming Securities and Greig Middleton. Before moving into investment, he worked in various commercial functions in the pharmaceutical industry for seven years. He holds a BSc (Hons) in Biological Sciences and an MSc in Business Administration from Edinburgh University. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Blake M. Paterson, Co-Founder & CEO, Cerecor, Inc. Physician-Executive / Entrepreneur with ability to lead drug hunting, translational medicine, product development, registration, finance & commercialization operations. Successful company builder with experience in licensing, marketing, strategic planning / portfolio management, global clinical research and affiliate operations within small and large organizations. Device and therapeutics tech transfer. Proven fundraiser, able to develop and communicate vision throughout the organization and in the marketplace. Successful in exploiting biomedical business opportunities in EU, North And South America; trilingual. Specialties: Clinical medicine, drug hunting, translational medicine, product development, registration, finance & commercialization operations in therapeutics and medical devices. Product licensing, marketing, strategic planning / portfolio management, global clinical research and affiliate operations within small and large organizations. Board Certified in Anesthesiology (ABA). Carina Schmidt, CEO, Athera Biotechnologies AB Carina is Chief Executive Officer, Athera Biotechnologies AB (publ), a Karolinska Development portfolio company. Ms Schmidt has experience from nearly 30 years in industry, mainly in business development, international marketing and product management within the Life Science area. Former management consultant, interim CEO and business advisor to several biotech start-ups. During years 1985 to 2000 she has worked with Pharmacia Biotech/Amersham Biosciences (now GE HealthCare), founded Grasp Bioscience AB in year 2000 and co-founded BioBusiness Partners Scandinavia in year 2006. Board Director in Genovis AB (publ) and Member of the Investment Committe in Innovationsbron AB Region Mitt. Lecturer in “Entrepreneurship in Biotechnology” at Umeå University and Umeå Biotech Incubator. Carlos Buesa, CEO, Oryzon Carlos earned his PhD in Biochemistry from the University of Barcelona in Spain. He has produced more than thirty papers and patents internationally, was a member of the cellular signaling research team in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the University of Ghent in Belgium, and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also in Belgium. In 2000, he founded Oryzon, one of the strongest-growing biotech companies in Spain, and since 2001 he has served as Chief Executive Officer and Chairman of the Board of Directors. In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He has taken the executive education programme (PADE) at the IESE Business School. Currently he is President of the Association of Catalan Biotechnology Companies CataloniaBio, and he is a member of the governing body of ASEBIO and of the Executive Committee of BioRegió de Catalunya, a new regional development model that has been set up with the aim of improving people’s quality of life through better coordination of the biotechnology activity being carried out in Catalonia. Carlos de Sousa, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH Carlos is Vice President, Head of Commercial Licensing at Takeda. He was previously Vice President of Corporate Licensing at Nycomed, which was acquired by Takeda in 2011. Prior to joining Takeda-Nycomed, Dr. de Sousa was Chief Business Officer at Newron Pharmaceuticals SpA in Italy, where he was responsible for the company’s growth strategy, including its in- and out-licensing, and mergers & acquisitions activities. Before Newron, Dr. de Sousa was Global Head of Business Development and Licensing at Schwarz Pharma AG in Germany and prior to that served as Head of Global Negotiations at Novartis Pharma AG, based in Switzerland. At the latter he was also European Business Head for the Respiratory and Dermatology Franchise. Dr. de Sousa started his career in the pharmaceutical industry with Pfizer in 1989, as Medical Director in Portugal. He then joined the Pfizer Corporation in New York, USA, where he was initially appointed International Medical Director and, subsequently, Director of Corporate Licensing and Development and Director of Medical and Regulatory Affairs for Latin America. Dr. de Sousa earned his M.D. degree from Lisbon University, Portugal in 1983 and his Executive M.B.A. from New York University, USA in 2000. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5: Speakers Alexey Eliseev, Managing D
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58:
CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60:
CONTACT Malcolm Weir Chief Executiv
Page 61 and 62:
CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64:
CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66:
CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68:
CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?